📰 Radio Conjugates News
Radio Conjugates News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Radio Conjugates. Real-time updates on events, politics, business and more.
May 23, 2024
Financing includes participation from new and existing investors Strengthens balance sheet, with pro forma cash position of approximately $1.0 billion, extending expected financial runway into the...
May 23, 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--May 23, 2024--
May 2, 2024
Multiple preclinical and clinical abstracts accepted for presentation at 2024 ASCO Annual Meeting and AACR Annual Meeting underscore breadth of Bicycle® platform technology and pipeline Continued...
April 24, 2024
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced the acceptance...
April 2, 2024
Bicycle Therapeutics plc , a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, today announced that management...
February 28, 2024
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Feb 28, 2024--
February 20, 2024
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer...
December 15, 2023
Bicycle Therapeutics (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, is today hosting a Research & Development (R&D) Day for investors and analysts in New York to provide clinical updates for BT8009, BT748
December 14, 2023
Nectin-4 portfolio comprised of BT8009 and BT7480 represents potential opportunity to become leader in treating Nectin-4-driven cancers, starting with metastatic urothelial cancer Updated BT8009...